Clínicos > Estudos Clínicos do HCC > SARAH >
Segurança e tolerabilidade


As microesferas de resina SIR-Spheres® Y-90 foram significativamente melhor toleradas do que o sorafenibe na população de segurança:

Eventos adversos significativamente menores e menos graves (EA)



Significativamente menos pacientes com EAs relacionados ao tratamento


AES mediana relacionada ao tratamento por paciente


Frequência e gravidade significativamente reduzidas de EAs


Visão geral dos eventos adversos na população de Segurança

As microesferas de resina SIR-Spheres Y-90 foram seguras e bem toleradas, com poucas complicações associadas ao SIRT

Não houve hepatite por radiação relacionada ao tratamento ou doença hepática induzida por radioembolização.

Vilgrain V et al.  Lancet Oncol 2017; 18: 1624–36.
Bouattour M et al.  Ann Oncol 2017; ESMO 19th WCGIC, Abs. LBA-001.




Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×